IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$72.62 USD
-0.03 (-0.04%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $72.64 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.62 USD
-0.03 (-0.04%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $72.64 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum C VGM
Zacks News
Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 11.11% and 1.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air (XAIR) delivered earnings and revenue surprises of 6.90% and 5.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Arcus Biosciences (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
by Zacks Equity Research
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
by Zacks Equity Research
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Intra-Cellular (ITCI) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 48.39% and 2.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
by Zacks Equity Research
Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
by Zacks Equity Research
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
by Zacks Equity Research
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of 7.88% and 4.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?